Determining Exposures when Transitioning Between Combination Treatments in Cystic Fibrosis: Trikafta
Many cystic fibrosis (CF) patients take several medications at one time to manage symptoms and the disease. In 2012, FDA approved Ivacaftor (Kalydeco®) for treatment of the underlying cause of CF in a small subset of the patient population. In 2015, a combination treatment of Ivacaftor and Lumacaftor (Orkambi®), followed by a combination of Ivacaftor and Texacaftor (Symdeko®) in 2018. In 2019, the first triple combination of Elexacaftor/Texacaftor/Ivacaftor (Trikafta®) for patients 12 and up, accounting for about 90% of patients with CF was approved.
“Today’s landmark approval is a testament to these efforts, making a novel treatment available to most cystic fibrosis patients, including adolescents, who previously had no options and giving others in the cystic fibrosis community access to an additional effective therapy,”